{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T22:51:06Z","timestamp":1789426266311,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s00415-025-13278-8","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:57:15Z","timestamp":1753189035000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["MOG-IgG detection in serum and cerebrospinal fluid: diagnostic implications and clinical correlates in adult-onset Chinese MOGAD patients"],"prefix":"10.1007","volume":"272","author":[{"given":"Yuwei","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxiang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5973-3653","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"9","key":"13278_CR1","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/s1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A et al (2021) Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 20(9):762\u2013772. https:\/\/doi.org\/10.1016\/s1474-4422(21)00218-0","journal-title":"Lancet Neurol"},{"key":"13278_CR2","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000674","author":"M Reindl","year":"2020","unstructured":"Reindl M, Schanda K, Woodhall M et al (2020) International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000674","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13278_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-018-1144-2","volume":"15","author":"S Jarius","year":"2018","unstructured":"Jarius S, Paul F, Aktas O et al (2018) MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation 15(1):134. https:\/\/doi.org\/10.1186\/s12974-018-1144-2","journal-title":"J Neuroinflammation"},{"issue":"1","key":"13278_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","volume":"17","author":"S Jarius","year":"2020","unstructured":"Jarius S, Pellkofer H, Siebert N et al (2020) Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 17(1):261. https:\/\/doi.org\/10.1186\/s12974-020-01824-2","journal-title":"J Neuroinflammation"},{"issue":"11","key":"13278_CR5","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/wnl.0000000000201662","volume":"100","author":"S Carta","year":"2023","unstructured":"Carta S, Cobo Calvo \u00c1, Armangu\u00e9 T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100(11):e1095\u2013e1108. https:\/\/doi.org\/10.1212\/wnl.0000000000201662","journal-title":"Neurology"},{"key":"13278_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001095","author":"YN Kwon","year":"2022","unstructured":"Kwon YN, Kim B, Kim JS et al (2022) Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF: clinical implication of testing and association with disability. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000001095","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"13278_CR7","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1093\/brain\/awad122","volume":"146","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto Y, Kaneko K, Takahashi T et al (2023) Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids. Brain 146(9):3938\u20133948. https:\/\/doi.org\/10.1093\/brain\/awad122","journal-title":"Brain"},{"issue":"1","key":"13278_CR8","doi-asserted-by":"publisher","first-page":"e2142780","DOI":"10.1001\/jamanetworkopen.2021.42780","volume":"5","author":"C Satukijchai","year":"2022","unstructured":"Satukijchai C, Mariano R, Messina S et al (2022) Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. JAMA Netw Open 5(1):e2142780\u2013e2142780. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42780","journal-title":"JAMA Netw Open"},{"issue":"11","key":"13278_CR9","doi-asserted-by":"publisher","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","volume":"100","author":"S Carta","year":"2023","unstructured":"Carta S, Cobo Calvo A, Armangue T et al (2023) Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study. Neurology 100(11):e1095\u2013e1108. https:\/\/doi.org\/10.1212\/WNL.0000000000201662","journal-title":"Neurology"},{"issue":"2\u20133","key":"13278_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/s0162-3109(00)00186-7","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC (2000) Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 47(2\u20133):63\u201383. https:\/\/doi.org\/10.1016\/s0162-3109(00)00186-7","journal-title":"Immunopharmacology"},{"issue":"1","key":"13278_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2174\/2772432817666220412110720","volume":"18","author":"VP Stamatellos","year":"2023","unstructured":"Stamatellos VP, Papazisis G (2023) Safety and monitoring of the treatment with disease-modifying therapies (DMTs) for multiple sclerosis (MS). Curr Rev Clin Exp Pharmacol 18(1):39\u201350. https:\/\/doi.org\/10.2174\/2772432817666220412110720","journal-title":"Curr Rev Clin Exp Pharmacol"},{"issue":"7","key":"13278_CR12","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","volume":"270","author":"S Jarius","year":"2023","unstructured":"Jarius S, Aktas O, Ayzenberg I et al (2023) Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis. J Neurol 270(7):3341\u20133368. https:\/\/doi.org\/10.1007\/s00415-023-11634-0","journal-title":"J Neurol"},{"issue":"1","key":"13278_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/wnl.0000000000012175","volume":"97","author":"T Akaishi","year":"2021","unstructured":"Akaishi T, Takahashi T, Misu T et al (2021) Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder. Neurology 97(1):e1\u2013e12. https:\/\/doi.org\/10.1212\/wnl.0000000000012175","journal-title":"Neurology"},{"issue":"5","key":"13278_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00401-021-02286-3","volume":"141","author":"S Carta","year":"2021","unstructured":"Carta S, H\u00f6ftberger R, Bolzan A et al (2021) Antibodies to MOG in CSF only: pathological findings support the diagnostic value. Acta Neuropathol 141(5):801\u2013804. https:\/\/doi.org\/10.1007\/s00401-021-02286-3","journal-title":"Acta Neuropathol"},{"issue":"3","key":"13278_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/s1474-4422(22)00431-8","volume":"22","author":"B Banwell","year":"2023","unstructured":"Banwell B, Bennett JL, Marignier R et al (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD Panel proposed criteria. Lancet Neurol 22(3):268\u2013282. https:\/\/doi.org\/10.1016\/s1474-4422(22)00431-8","journal-title":"Lancet Neurol"},{"key":"13278_CR16","doi-asserted-by":"publisher","first-page":"1260358","DOI":"10.3389\/fneur.2023.1260358","volume":"14","author":"JY Hor","year":"2023","unstructured":"Hor JY, Fujihara K (2023) Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol 14:1260358. https:\/\/doi.org\/10.3389\/fneur.2023.1260358","journal-title":"Front Neurol"},{"issue":"1","key":"13278_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/jnnp-2012-302925","volume":"84","author":"S Yoshimura","year":"2013","unstructured":"Yoshimura S, Isobe N, Matsushita T et al (2013) Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status. J Neurol Neurosurg Psychiatry 84(1):29\u201334. https:\/\/doi.org\/10.1136\/jnnp-2012-302925","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"13278_CR18","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1177\/1352458510391345","volume":"17","author":"W Qiu","year":"2011","unstructured":"Qiu W, James I, Carroll WM et al (2011) HLA-DR allele polymorphism and multiple sclerosis in Chinese populations: a meta-analysis. Mult Scler 17(4):382\u2013388. https:\/\/doi.org\/10.1177\/1352458510391345","journal-title":"Mult Scler"},{"key":"13278_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000702","author":"AL Bruijstens","year":"2020","unstructured":"Bruijstens AL, Wong YYM, van Pelt DE et al (2020) HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/nxi.0000000000000702","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"13278_CR20","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/acn3.51378","volume":"8","author":"M Grant-Peters","year":"2021","unstructured":"Grant-Peters M, Passos GRD, Yeung HY et al (2021) No strong HLA association with MOG antibody disease in the UK population. Ann Clin Transl Neurol 8(7):1502\u20131507. https:\/\/doi.org\/10.1002\/acn3.51378","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"13278_CR21","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/jnnp-2019-322115","volume":"91","author":"X Sun","year":"2020","unstructured":"Sun X, Qiu W, Wang J et al (2020) Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. J Neurol Neurosurg Psychiatry 91(7):733\u2013739. https:\/\/doi.org\/10.1136\/jnnp-2019-322115","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"13278_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41435-022-00192-6","volume":"24","author":"SJ Virolainen","year":"2023","unstructured":"Virolainen SJ, VonHandorf A, Viel K et al (2023) Gene-environment interactions and their impact on human health. Genes Immun 24(1):1\u201311. https:\/\/doi.org\/10.1038\/s41435-022-00192-6","journal-title":"Genes Immun"},{"issue":"1","key":"13278_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 13(1):279. https:\/\/doi.org\/10.1186\/s12974-016-0717-1","journal-title":"J Neuroinflammation"},{"issue":"1","key":"13278_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","volume":"16","author":"A Cobo-Calvo","year":"2019","unstructured":"Cobo-Calvo A, Sep\u00falveda M, Rollot F et al (2019) Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 16(1):134. https:\/\/doi.org\/10.1186\/s12974-019-1525-1","journal-title":"J Neuroinflammation"},{"issue":"2","key":"13278_CR25","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1212\/wnl.0000000000009758","volume":"95","author":"JJ Chen","year":"2020","unstructured":"Chen JJ, Flanagan EP, Bhatti MT et al (2020) Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology 95(2):e111\u2013e120. https:\/\/doi.org\/10.1212\/wnl.0000000000009758","journal-title":"Neurology"},{"key":"13278_CR26","doi-asserted-by":"publisher","first-page":"577987","DOI":"10.1016\/j.jneuroim.2022.577987","volume":"373","author":"P Sutton","year":"2022","unstructured":"Sutton P, Lutz MW, Hartsell FL et al (2022) Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: presentation and outcomes of adults at a single center. J Neuroimmunol 373:577987. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577987","journal-title":"J Neuroimmunol"},{"issue":"1","key":"13278_CR27","doi-asserted-by":"publisher","first-page":"103693","DOI":"10.1016\/j.autrev.2024.103693","volume":"24","author":"BP Trewin","year":"2025","unstructured":"Trewin BP, Brilot F, Reddel SW et al (2025) MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev 24(1):103693. https:\/\/doi.org\/10.1016\/j.autrev.2024.103693","journal-title":"Autoimmun Rev"},{"issue":"21","key":"13278_CR28","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/wnl.0000000000005560","volume":"90","author":"A Cobo-Calvo","year":"2018","unstructured":"Cobo-Calvo A, Ruiz A, Maillart E et al (2018) Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 90(21):e1858\u2013e1869. https:\/\/doi.org\/10.1212\/wnl.0000000000005560","journal-title":"Neurology"},{"key":"13278_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","volume":"195","author":"JJ Chen","year":"2018","unstructured":"Chen JJ, Flanagan EP, Jitprapaikulsan J et al (2018) Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol 195:8\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2018.07.020","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"13278_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4274\/balkanmedj.galenos.2024.2024-1-97","volume":"41","author":"S Ko\u00e7","year":"2024","unstructured":"Ko\u00e7 S, \u015een S, Terzi Y et al (2024) Clinical, demographic, and radiological characteristics of patients demonstrating antibodies against myelin oligodendrocyte glycoprotein. Balkan Med J 41(4):272\u2013279. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2024.2024-1-97","journal-title":"Balkan Med J"},{"issue":"4","key":"13278_CR31","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","volume":"75","author":"Y Hacohen","year":"2018","unstructured":"Hacohen Y, Wong YY, Lechner C et al (2018) Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurol 75(4):478\u2013487. https:\/\/doi.org\/10.1001\/jamaneurol.2017.4601","journal-title":"JAMA Neurol"},{"issue":"5","key":"13278_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000257","volume":"3","author":"M Spadaro","year":"2016","unstructured":"Spadaro M, Gerdes LA, Krumbholz M et al (2016) Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(5):e257. https:\/\/doi.org\/10.1212\/nxi.0000000000000257","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13278_CR33","doi-asserted-by":"publisher","first-page":"103229","DOI":"10.1016\/j.msard.2021.103229","volume":"56","author":"SE Epstein","year":"2021","unstructured":"Epstein SE, Levin S, Onomichi K et al (2021) Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses. Mult Scler Relat Disord 56:103229. https:\/\/doi.org\/10.1016\/j.msard.2021.103229","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13278-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13278-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13278-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T02:42:59Z","timestamp":1756608179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13278-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["13278"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13278-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University and was carried out in compliance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for participation and publication was obtained from involved patients or their legal guardians.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"528"}}